Harmony Biosciences Holdings (HRMY)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Long-term debt US$ in thousands 163,016 167,847 171,422 174,996 178,566 182,131 180,487 185,063 189,647 189,725 189,807 189,896 189,984 190,069 195,610
Total stockholders’ equity US$ in thousands 659,155 596,804 538,583 515,394 466,992 481,332 485,172 443,041 402,838 343,884 246,533 214,503 186,507 152,018 126,551
Debt-to-equity ratio 0.25 0.28 0.32 0.34 0.38 0.38 0.37 0.42 0.47 0.55 0.77 0.89 1.02 1.25 1.55

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $163,016K ÷ $659,155K
= 0.25

The debt-to-equity ratio of Harmony Biosciences Holdings has been showing a declining trend over the analyzed period. Starting at 1.55 in June 2021, the ratio decreased steadily to 0.25 by December 2024. This downward trend indicates that the company has been reducing its reliance on debt financing in relation to equity, which can be seen as a positive sign of improved financial stability and lower financial risk. The decreasing ratio suggests that the company is progressively using less debt in its capital structure compared to equity, which may be attributed to effective financial management strategies or improved profitability over the period. Overall, a lower debt-to-equity ratio is generally considered favorable as it indicates a lower level of financial leverage and potential financial risk for the company.